The Filing Desk

PacBio

PACB · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PACB · Last close · November 13, 2026
$1.96
Value PacBio yourself

PacBio's revenue rose 3.9% to $160 million in fiscal 2025. Its operating margin was −346.1%, down from −308.0% a year earlier. Free cash flow was −$114 million. The diluted share count rose 4.0%.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001299130-26-000034 Updated
Revenue
$160M
3.9%
Operating margin
−346.1%
38.2 pts
Net income
−$546M
 
Free cash flow
−$114M
 
Return on capital
−77.1%
33.7 pts
Market cap
$610M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What PacBio does

Pacific Biosciences, known as PacBio, makes machines that read DNA. Its HiFi long-read sequencing reads much longer stretches of DNA at a time than older methods, which helps researchers see complex parts of the genome. Its instruments are the Revio, Vega and Sequel systems, which read DNA on small chips called SMRT Cells. It sells the instruments, plus the SMRT Cells, other consumables and software they need.

Its customers include university and government research institutes, commercial testing and service labs, genome centers, public health labs, hospitals, contract research organizations, drug companies and agricultural companies. The uses range from human genetic disease and cancer to plant and animal science and infectious disease.

On January 30, 2026, PacBio sold assets for its short-read sequencing technology to Illumina, a competitor. Illumina paid $50.0 million in cash and took on certain liabilities, and PacBio kept a non-exclusive license to some of the technology. PacBio has lost money so far and is cutting costs. It says it is not cash flow positive and that it may not have enough cash to make its debt payments.

Its biggest risks, as it describes them

  • Losses to date, with no assurance it will ever become profitable.
  • Not being cash flow positive, and possibly lacking cash for debt payments and long-term plans.
  • Cost-cutting that could disrupt its operations without delivering the expected savings.
  • The sale of its short-read sequencing assets, which could hurt its business.
  • Failing to develop, make and sell its current and new products, and leadership changes.
From PacBio's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

PacBio lost money in fiscal 2025: a net loss of $546 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,044772631390280
Debt incl. finance leases898898893648645
Net debt (negative means net cash)−147126261258366
Net debt to EBITDA—————
Debt to equity1.1x1.6x1.3x1.3x—
Interest coverage−16.8x−20.9x−23.3x−35.4x−79.7x
Current ratio15.4x3.2x7.8x7.5x5.2x
Quick ratio15.0x3.0x7.2x6.6x4.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project PacBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What PacBio says to expect

  • Full year 2026: revenuePacBio now expects revenue for the full year 2026 to be in the range of $155 million to $160 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of PacBio reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 92 of 93 of 9
Rule of 40−77.4%−161.0%−67.3%
Altman Z''−1.59−5.15−13.42
Accruals ratio−2.7%−6.9%−42.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassFailPass
F-score3 of 92 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put PacBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PacBioFY253.9%−346.1%−71.2%−77.1%—3
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———Compare
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
Maravai LifeSciencesFY25−28.3%−115.9%−38.1%−32.0%—2Compare
Cytek BiosciencesFY250.5%−20.0%−4.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue9194799179130128200154160
Revenue growth−2.2%3.0%−15.9%15.6%−13.2%65.4%−1.7%56.3%−23.2%3.9%
Gross profit44352535335949533746
Research and development686563606411319318713597
Operating income−71−90−101−100−104−210−307−334−474−554
Net income−74−92−103−8429−181−314−307−310−546
Diluted EPS (US$)−0.83−0.87−0.76−0.550.17−0.89−1.40−1.21−1.59−1.82
Diluted shares (millions)89106135152175204224254288300
Cash flow
Cash from operations−68−68−66−7820−111−263−259−206−111
Capital expenditure810231617963
Free cash flow−76−78−68−8118−117−280−268−212−114
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation20202316187379727142
Balance sheet at fiscal year end
Cash and short-term investments7263102493191,044772631390280
Debt incl. finance leases16141516—898898893648645
Total assets1381441701484142,0071,7671,7461,260784
Total liabilities53585693781,2161,2041,045754779
Shareholders' equity8586114553367915637015075
Margins and ratios
Gross margin48.7%37.1%31.9%38.0%41.3%45.1%38.2%26.3%24.2%28.6%
Operating margin−78.5%−96.1%−128.4%−110.6%−132.3%−161.2%−239.4%−166.8%−308.0%−346.1%
Net margin−82.0%−98.6%−130.4%−92.6%37.3%−138.8%−244.9%−153.0%−201.2%−341.5%
Free cash flow margin−83.9%−83.4%−86.8%−89.3%23.4%−89.7%−218.2%−133.7%−137.8%−71.2%
Rule of 40 (growth + FCF margin)−86.2%−80.4%−102.7%−73.7%10.2%−24.3%−219.9%−77.4%−161.0%−67.3%
Return on capital−321.7%−216.2%−252.4%−330.6%——−36.4%−32.0%−43.4%−77.1%
Return on equity−94.0%−108.0%−102.5%−99.6%15.1%−32.2%−46.4%−48.5%−51.3%−213.4%
Return on assets−55.3%−65.4%−65.2%−52.9%10.5%−15.0%−16.6%−17.5%−20.6%−53.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: PacBio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with PacBio.